"PSOGEN:Effect adalimumab op zelfbeeld en seksueel functioneren bij matige en ernstige psoriasis van de anogenitale regio; prospectief, open label pilot onderzoek"

Trial Profile

"PSOGEN:Effect adalimumab op zelfbeeld en seksueel functioneren bij matige en ernstige psoriasis van de anogenitale regio; prospectief, open label pilot onderzoek"

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 04 Jan 2013

At a glance

  • Drugs Adalimumab (Primary)
  • Indications Psoriasis
  • Focus Therapeutic Use
  • Acronyms PSOGEN
  • Sponsors Abbott Laboratories
  • Most Recent Events

    • 17 Jun 2011 Planned End Date changed to 1 Oct 2011 as reported in the European Clinical Trials Registry record.
    • 16 Jun 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top